<DOC>
	<DOC>NCT00984113</DOC>
	<brief_summary>The purpose of the study is to determine the pharmacokinetics and safety of elinogrel and its metabolite in patients with mild, moderate, and severe renal impairment compared to healthy volunteers.</brief_summary>
	<brief_title>Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment</brief_title>
	<detailed_description>Multiple-dose, open-label parallel-group design in patients with mild, moderate or severe renal impairment and age (±7 years), sex and weight (±15% BMI) matched healthy subjects. - mild renal impairment: CrCl from 50 to ≤80 ml/min - moderate renal impairment: CrCl from 30 to &lt;50 ml/min - severe renal impairment: CrCl of &lt;30 ml/min</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Able to understand and sign the written informed consent Subjects should have either normal renal function or have stable renal disease History of heart disease Unstable or clinically significant other disorders such as respiratory, hepatic, metabolic, psychiatric or gastrointestinal disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Elinogrel</keyword>
	<keyword>Renal impairment</keyword>
	<keyword>Healthy</keyword>
	<keyword>Kidney dysfunction</keyword>
</DOC>